ArticleFrontiers in medicine2026
Clinical efficacy of Jianqiao ancient moxibustion in treating chronic fatigue syndrome: a single-center randomized controlled superiority trial protocol.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic fatigue syndrome (CFS) is a widespread and debilitating disorder that profoundly impacts the physical and mental health of patients. In traditional Chinese medicine (TCM), spleen-kidney yang deficiency is recognized as the most prevalent syndrome associated with CFS. Moxibustion is commonly employed to mitigate fatigue and address yang deficiency; however, conventional moxa box moxibustion has demonstrated limited clinical efficacy in practice. Considering the intrinsic benefits of Jianqiao ancient moxibustion in terms of its herbal formula and treatment coverage, this randomized controlled superiority trial aims to compare the clinical efficacy of Jianqiao ancient moxibustion with that of moxa box moxibustion in patients with CFS who exhibit a spleen-kidney yang deficiency pattern. Methods: This single-center, single-blind randomized controlled superiority trial will enroll 90 eligible patients diagnosed with CFS exhibiting a spleen-kidney yang deficiency pattern. Participants will be randomly assigned in a 1:1 ratio to receive either Jianqiao ancient moxibustion or moxa box moxibustion, with each group receiving standardized interventions as outlined in the trial protocol. Each 60-min treatment session will be administered three times per week for 4 consecutive weeks. A follow-up assessment will be conducted at week 16. The primary outcome measure will be the Fatigue Scale-14. Secondary outcome measures will include the Spleen-Kidney Yang Deficiency Symptom Scale, the Self-Rating Anxiety Scale, the Self-Rating Depression Scale, and infrared thermal imaging. All evaluations will be performed at baseline, immediately post-intervention at week 4, and during follow-up at week 16. Discussion: It is hypothesized that Jianqiao ancient moxibustion will be more effective than moxa box moxibustion in alleviating symptoms in patients with CFS who have spleen-kidney yang deficiency. Furthermore, this study will employ infrared thermal imaging to assess alterations in the thermal characteristics of the Sanjiao and Governor Vessel both prior to and following moxibustion. This methodology may help elucidate the mechanisms underlying moxibustion's modulation of yang-qi distribution in patients with CFS. Study protocol registration: https://www.chictr.org.cn/showproj.html?proj=193045.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.